Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Terminated 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 41Lymphoid 10Other hematologic neoplasm 6Thoracic 2Gastrointestinal 2CNS 2Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Bortezomib × Other solid neoplasm × Clear all
NCT00996385 2011-10-31

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

Columbia University

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡